Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BCL9 | O00512 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8642223 | 0.84 | MAPT (0.64) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL7139968 | 0.84 | MAPT (0.67) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL5692340 | 0.83 | MAPT (0.66) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL1508442 | 0.83 | MAPT (0.66) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL5692343 | 0.83 | MAPT (0.66) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL7138665 | 0.82 | MAPT (0.64) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL7720668 | 0.82 | MAPT (0.64) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL27513490 | 0.81 | FFAR1 (0.46) | MAPTLMNAKDM4EFFAR1ALDH1A1 | |
| SCHEMBL1508345 | 0.81 | FFAR1 (0.49) | KDM4EFFAR1ALDH1A1 | |
| SCHEMBL1508392 | 0.80 | FFAR1 (0.81) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | MAPT 4809/4885LMNA 2035/4885KDM4E 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.